Caring Ambassadors Program

Hepatitis C Newsletter

www.HepCChallenge.org

July 2011

 

Clinical Trials, Cohort Studies, Pilot Studies

 

Outcomes of treatment for hepatitis C virus infection by primary care providers. Arora S, Thornton K, Murata G, et al. N Engl J Med. 2011 Jun 9;364(23):2199-207. Epub 2011 Jun 1.

http://www.ncbi.nlm.nih.gov/pubmed/21631316

 

Genetic variation in interleukin 28B with respect to vertical transmission of hepatitis C virus and spontaneous clearance in HCV-infected children. Ruiz-Extremera A, Muñoz-Gámez JA, Salmerón-Ruiz MA, et al. Hepatology. 2011 Jun;53(6):1830-8. doi: 10.1002/hep.24298.

http://www.ncbi.nlm.nih.gov/pubmed/21413051

 

Telaprevir for retreatment of HCV infection. Zeuzem S, Andreone P, Pol S, et al. N Engl J Med. 2011 Jun 23;364(25):2417-28.

http://www.ncbi.nlm.nih.gov/pubmed/21696308

 

A Poxvirus Vaccine Is Safe, Induces T-Cell Responses, and Decreases Viral Load in Patients With Chronic Hepatitis C. Habersetzer F, Honnet G, Bain C, et al. Gastroenterology. 2011 Jun 13. [Epub ahead of print]

http://www.ncbi.nlm.nih.gov/pubmed/21699798 

 

Rate of Progression of Hepatic Fibrosis in Patients with Chronic Hepatitis C: Results from the HALT-C Trial. Hoefs JC, Shiffman ML, Goodman ZD, et al. Gastroenterology. 2011 Jun 12. [Epub ahead of print]

http://www.ncbi.nlm.nih.gov/pubmed/21699796

 

Optimal follow-up time to determine the sustained virological response in patients with chronic hepatitis C receiving Peg-IFN and ribavirin. Namikawa M, Kakizaki S, Yata Y, et al. J Gastroenterol Hepatol. 2011 Jun 7. doi: 10.1111/j.1440-1746.2011.06802.x. [Epub ahead of print]

http://www.ncbi.nlm.nih.gov/pubmed/21649727

 

Prognostic factors in patients with hepatitis C virus infection and systemic vasculitis. Terrier B, Semoun O, Saadoun D, Sène D, Resche-Rigon M, Cacoub P. Arthritis Rheum. 2011 Jun;63(6):1748-57. doi: 10.1002/art.30319.

http://www.ncbi.nlm.nih.gov/pubmed/21400476

 

A prospective study of T- and B-lymphocyte subpopulations, CD81 expression levels on B cells and regulatory CD4(+) CD25(+) CD127(low/-) FoxP3(+) T cells in patients with chronic HCV infection during pegylated interferon-alpha2a plus ribavirin treatment.

Soldevila B, Alonso N, Martínez-Arconada MJ, et al. J Viral Hepat. 2011 Jun;18(6):384-92. doi: 10.1111/j.1365-2893.2010.01317.x.

http://www.ncbi.nlm.nih.gov/pubmed/20487258

 

All-Cause, Liver-Related, and Non-Liver-Related Mortality Among HCV-Infected Individuals in the General US Population. El-Kamary SS, Jhaveri R, Shardell MD. Clin Infect Dis. 2011 Jul;53(2):150-7. Epub 2011 Jun 10.

http://www.ncbi.nlm.nih.gov/pubmed/21665867

 

Effect of combined siRNA of HCV E2 gene and HCV receptors against HCV. Jahan S, Khaliq S, Samreen B, et al. Virol J. 2011 Jun 10;8(1):295. [Epub ahead of print]

http://www.ncbi.nlm.nih.gov/pubmed/21663667

 

Cyclosporine A-Based Immunosuppression Reduces Relapse Rate After Antiviral Therapy in Transplanted Patients With Hepatitis C Virus Infection: A Large Multicenter Cohort Study. ReViS-TC Study Group. Transplantation. 2011 Jun 8. [Epub ahead of print]

http://www.ncbi.nlm.nih.gov/pubmed/21659948

 

Randomised clinical trial: anti-viral activity of ANA773, an oral inducer of endogenous interferons acting via TLR7, in chronic HCV. Bergmann JF, de Bruijne J, Hotho DM, et al. Aliment Pharmacol Ther. 2011 Jun 26. doi: 10.1111/j.1365-2036.2011.04745.x. [Epub ahead of print]

http://www.ncbi.nlm.nih.gov/pubmed/21707679

 

Genome-wide association study identified ITPA/DDRGK1 variants reflecting thrombocytopenia in pegylated interferon and ribavirin therapy for chronic hepatitis C.

Tanaka Y, Kurosaki M, Nishida N, et al. Hum Mol Genet. 2011 Jun 23. [Epub ahead of print]

http://www.ncbi.nlm.nih.gov/pubmed/21659334

 

Prediction of Sustained Virological Response to Combination Therapy with Pegylated Interferon Alfa and Ribavirin in Patients with Genotype 3 Chronic Hepatitis C. Tohra SK, Taneja S, Ghosh S, et al. Dig Dis Sci. 2011 Jun 25. [Epub ahead of print]

http://www.ncbi.nlm.nih.gov/pubmed/21706207

 

Retreatment of patients with chronic hepatitis C relapsers to a previous antiviral treatment. Floreani A, Cazzagon N, Furlan P, et al. Eur J Gastroenterol Hepatol. 2011 Jun 4. [Epub ahead of print]

http://www.ncbi.nlm.nih.gov/pubmed/21654322

 

Peginterferon Alfa-2a Is Superior to Peginterferon Alfa-2b in the Treatment of Naïve Patients with Hepatitis C Virus Infection: Meta-Analysis of Randomized Controlled Trials.

Singal AK, Jampana SC, Anand BS. Dig Dis Sci. 2011 Jun 4. [Epub ahead of print]

http://www.ncbi.nlm.nih.gov/pubmed/21643737

 

Retreatment of Hepatitis C with Consensus Interferon and Ribavirin After Nonresponse or Relapse to Pegylated Interferon and Ribavirin: A National VA Clinical Practice Study.

Yee HS, Currie SL, Tortorice K, et al. Dig Dis Sci. 2011 Jun 2. [Epub ahead of print]

http://www.ncbi.nlm.nih.gov/pubmed/21633833

 

Role of Interleukin 28B rs12979860 C/T Polymorphism on the Histological Outcome of Chronic Hepatitis C: Relationship with Gender and Viral Genotype. Falleti E, Bitetto D, Fabris C, et al. J Clin Immunol. 2011 Jun 7. [Epub ahead of print]

http://www.ncbi.nlm.nih.gov/pubmed/21647799

 

Serodiagnosis of Helicobacter hepaticus infection in patients with liver and gastrointestinal diseases: western blot analysis and ELISA using a highly specific monoclonal antibody for H. hepaticus antigen. Murakami K, Takahashi R, Ono M, et al. J Gastroenterol. 2011 Jun 8. [Epub ahead of print]

http://www.ncbi.nlm.nih.gov/pubmed/21656014

 

Basic and Applied Science, Pre-Clinical Studies

 

Common genetic polymorphism of ITPA gene affects ribavirin-induced anemia and effect of peg-interferon plus ribavirin therapy. Azakami T, Hayes CN, Sezaki H, et al. J Med Virol. 2011 Jun;83(6):1048-57. doi: 10.1002/jmv.22069.

http://www.ncbi.nlm.nih.gov/pubmed/21503919

 

Low doses of the novel caspase-inhibitor GS-9450 leads to lower caspase-3 and -8 expression on peripheral CD4+ and CD8+ T-cells. Arends JE, Hoepelman AI, Nanlohy NM, et al. Apoptosis. 2011 Jun 11. [Epub ahead of print]

http://www.ncbi.nlm.nih.gov/pubmed/21667042

 

Preexisting drug-resistance mutations reveal unique barriers to resistance for distinct antivirals. Robinson M, Tian Y, Delaney WE 4th, Greenstein AE. Proc Natl Acad Sci U S A. 2011 Jun 21;108(25):10290-5. Epub 2011 Jun 6.

http://www.ncbi.nlm.nih.gov/pubmed/21646519

 

Effects of hepatitis C virus on suppressor of cytokine signaling mRNA levels: comparison between different genotypes and core protein sequence analysis. Pascarella S, Clément S, Guilloux K, Conzelmann S, Penin F, Negro F. J Med Virol. 2011 Jun;83(6):1005-15. doi: 10.1002/jmv.22072.

http://www.ncbi.nlm.nih.gov/pubmed/21503913

 

A genetically humanized mouse model for hepatitis C virus infection. Dorner M, Horwitz JA, Robbins JB, et al. Nature. 2011 Jun 8;474(7350):208-11. doi: 10.1038/nature10168.

http://www.ncbi.nlm.nih.gov/pubmed/21654804

 

Sequence heterogeneity of NS5A and core proteins of hepatitis C virus and virological responses to pegylated-interferon/ribavirin combination therapy. El-Shamy A, Shoji I, Saito T, et al. Microbiol Immunol. 2011 Jun;55(6):418-26. doi: 10.1111/j.1348-0421.2011.00331.x.

http://www.ncbi.nlm.nih.gov/pubmed/21371092

 

Neurotoxic effects of the HCV core protein are mediated by sustained activation of ERK via TLR2 signaling. Paulino AD, Ubhi K, Rockenstein E, et al. J Neurovirol. 2011 Jun 10. [Epub ahead of print]

http://www.ncbi.nlm.nih.gov/pubmed/21660601

 

HIV/HCV/HBV Coinfection

 

Molecular characterization of hepatitis C virus genotype 4 sequences in HIV-coinfected patients from Argentina. Bolcic F, Jones LR, Laufer N, Quarleri J. J Med Virol. 2011 Jun;83(6):935-40. doi: 10.1002/jmv.22068.

http://www.ncbi.nlm.nih.gov/pubmed/21503903

 

Liver Toxicity of Antiretroviral Combinations Including Fosamprenavir Plus Ritonavir 1400/100 mg Once Daily in HIV/Hepatitis C Virus-Coinfected Patients. Merchante N, López-Cortés LF, Delgado-Fernández M, et al. AIDS Patient Care STDS. 2011 Jun 20. [Epub ahead of print]

http://www.ncbi.nlm.nih.gov/pubmed/21688986

 

Do rates of unprotected anal intercourse among HIV-positive MSM present a risk for hepatitis C transmission? Stall R, Wei C, Raymond HF, McFarland W. Sex Transm Infect. 2011 Jun 8. [Epub ahead of print]

http://www.ncbi.nlm.nih.gov/pubmed/21653934

 

 

Presence of occult HBV, but near absence of active HBV and HCV infections in people infected with HIV in rural South Africa. Barth RE, Huijgen Q, Tempelman HA, et al. J Med Virol. 2011 Jun;83(6):929-34. doi: 10.1002/jmv.22026.

http://www.ncbi.nlm.nih.gov/pubmed/21503902

 

Ethnic differences in viral dominance patterns in patients with hepatitis B virus and hepatitis C virus dual infection. Nguyen LH, Ko S, Wong SS, et al. Hepatology. 2011 Jun;53(6):1839-45. doi: 10.1002/hep.24308.

http://www.ncbi.nlm.nih.gov/pubmed/21425314

 

The Relation of HLA Genotype to Hepatitis C Viral Load and Markers of Liver Fibrosis in HIV-Infected and HIV-Uninfected Women. Kuniholm MH, Gao X, Xue X, et al. J Infect Dis. 2011 Jun;203(12):1807-14.

http://www.ncbi.nlm.nih.gov/pubmed/21606539

 

Concomitant Highly Active Antiretroviral Therapy Leads to Smaller Decline and Faster Recovery of CD4+ Cell Counts During and After Pegylated Interferon Plus Ribavirin Therapy in HIV-Hepatitis C Virus Coinfected Patients. Reiberger T, Payer BA, Kosi L, et al. J Infect Dis. 2011 Jun;203(12):1802-1806.

http://www.ncbi.nlm.nih.gov/pubmed/21606538

 

Twice-weekly pegylated interferon-α-2a and ribavirin results in superior viral kinetics in HIV/hepatitis C virus co-infected patients compared to standard therapy. Murphy AA, Herrmann E, Osinusi AO, et al. AIDS. 2011 Jun 1;25(9):1179-1187.

http://www.ncbi.nlm.nih.gov/pubmed/21593619

 

Influence of Interleukin-28B Single-Nucleotide Polymorphisms on Progression to Liver Cirrhosis in Human Immunodeficiency Virus-Hepatitis C Virus-Coinfected Patients Receiving Antiretroviral Therapy. Barreiro P, Pineda JA, Rallón N, et al. J Infect Dis. 2011 Jun;203(11):1629-36.

http://www.ncbi.nlm.nih.gov/pubmed/21592993

 

Epidemiology, Diagnostics, and Miscellaneous Works

 

Estimated Risk of Human Immunodeficiency Virus and Hepatitis C Virus Infection among Potential Organ Donors from 17 Organ Procurement Organizations in the United States.

Ellingson K, Seem D, Nowicki M, et al. Am J Transplant. 2011 Jun;11(6):1201-1208. doi: 10.1111/j.1600-6143.2011.03518.x.

http://www.ncbi.nlm.nih.gov/pubmed/21645253

 

Hepatitis C Virus Adversely Affects Quality of Life. Cillo U, Amodio P, Ronco C, et al. Blood Purif. 2011 Jun 10;32(2):144-149. [Epub ahead of print]

Soni SS, Zanus G, Minazzato L, Salari A, Neri D, Bombonato G, Schiff S, Bianco T.

http://www.ncbi.nlm.nih.gov/pubmed/21659741

 

Education by a Nurse Increases Response of Patients With Chronic Hepatitis C to Therapy With Peginterferon-alfa2a and Ribavirin. Larrey D, Salse A, Ribard D, et al. Clin Gastroenterol Hepatol. 2011 Jun 6. [Epub ahead of print]

http://www.ncbi.nlm.nih.gov/pubmed/21683161

 

Clarification of interspousal hepatitis C virus infection in acute hepatitis C patients by molecular evolutionary analyses: Consideration on sexual and non-sexual transmission between spouses. Nakamura I, Tanaka Y, Ochiai K, Moriyasu F, Mizokami M, Imawari M. Hepatol Res. 2011 Jun 23. doi: 10.1111/j.1872-034X.2011.00843.x. [Epub ahead of print]

http://www.ncbi.nlm.nih.gov/pubmed/21699638

 

Directly acting antivirals against hepatitis C virus. Soriano V, Vispo E, Poveda E, et al. J Antimicrob Chemother. 2011 Jun 7. [Epub ahead of print]

http://www.ncbi.nlm.nih.gov/pubmed/21652618

 

Patient acceptance of universal screening for hepatitis C virus infection. Coffin PO, Stevens AM, Scott JD, Stekler JD, Golden MR. BMC Infect Dis. 2011 Jun 6;11:160.

http://www.ncbi.nlm.nih.gov/pubmed/21645388

 

Role of Lifestyle Changes in the Management of Chronic Liver Disease. Nobili V, Carter-Kent C, Feldstein AE. BMC Med. 2011 Jun 6;9(1):70. [Epub ahead of print]

http://www.ncbi.nlm.nih.gov/pubmed/21645344

 

Liver Cancer

 

Hepatitis C virus infection induces the expression of amphiregulin, a factor related to the activation of cellular survival pathways and required for efficient viral assembly. Pei R, Chen H, Lu L, et al. J Gen Virol. 2011 Jun 8. [Epub ahead of print]

http://www.ncbi.nlm.nih.gov/pubmed/21653755

 

Amino acid substitutions in hepatitis C virus core region predict hepatocarcinogenesis following eradication of HCV RNA by antiviral therapy. Akuta N, Suzuki F, Hirakawa M, et al. J Med Virol. 2011 Jun;83(6):1016-22. doi: 10.1002/jmv.22094.

http://www.ncbi.nlm.nih.gov/pubmed/21503914

 

Hepatocellular nodules in liver cirrhosis: MR evaluation. Lee JM, Choi BI. Abdom Imaging. 2011 Jun;36(3):282-9.

http://www.ncbi.nlm.nih.gov/pubmed/21399975

 

Rising incidence and demographics of hepatocellular carcinoma in the USA: what does it mean? Shaw JJ, Shah SA. Expert Rev Gastroenterol Hepatol. 2011 Jun;5(3):365-70.

http://www.ncbi.nlm.nih.gov/pubmed/21651354

 

Impact of Pegylated Interferon Therapy on Outcomes of Patients with Hepatitis C Virus-Related Hepatocellular Carcinoma After Curative Hepatic Resection. Tanimoto Y, Tashiro H, Aikata H, et al. Ann Surg Oncol. 2011 Jun 28. [Epub ahead of print]

http://www.ncbi.nlm.nih.gov/pubmed/21710324

 

Serum levels of β-catenin as a potential marker for genotype 4/hepatitis C-associated hepatocellular carcinoma. Zekri AR, Bahnassy AA, Alam El-Din HM, et al. Oncol Rep. 2011 Jun 21. doi: 10.3892/or.2011.1355. [Epub ahead of print]

http://www.ncbi.nlm.nih.gov/pubmed/21701780

 

Diagnostic significance of plasma osteopontin in hepatitis C virus-related hepatocellular carcinoma. Abu El Makarem MA, Abdel-Aleem A, Ali A, Saber R, et al. Ann Hepatol. 2011 Jun 1;10(3):296-305.

http://www.ncbi.nlm.nih.gov/pubmed/21677331